Tucotuzumab celmoleukin

Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).[1][2][3]

Tucotuzumab celmoleukin
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetEpCAM
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC7812H12124N2044O2408S60
Molar mass175130.42 g·mol−1
  (verify)

This drug was developed by EMD Pharmaceuticals.

References
  1. Statement On A Nonproprietary Name Adopted By The Usan Council - Tucotuzumab Celmoleukin, American Medical Association.
  2. ClinicalTrials.gov
  3. National Cancer Institute: Definition of tucotuzumab celmoleukin


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.